Direct effects of dexamethasone on human podocytes  by Xing, C.-Y. et al.
Direct effects of dexamethasone on human
podocytes
C-Y Xing1,2, MA Saleem1, RJ Coward1, L Ni1, IR Witherden1 and PW Mathieson1
1Academic Renal Unit, University of Bristol, Southmead Hospital, Bristol, UK and 2The First Affiliated Hospital, Nanjing Medical
University, Nanjing, People’s Republic of China
Glucocorticoids are widely used in the treatment of human
glomerular diseases, but their mode of action is poorly
understood particularly in steroid-sensitive nephrotic
syndrome, which is most common in childhood and is
characterized by a lack of inflammation in the kidney.
The podocyte is a key cell in the glomerulus in health and
disease: until recently, human podocytes have been difficult
to study in vitro. We have developed a conditionally
immortalized human podocyte cell line transfected with
a temperature-sensitive simian virus 40 transgene: when
the transgene is inactivated in vitro, these cells adopt the
phenotype of differentiated podocytes. We have used these
cells to evaluate, using immunocytochemistry, reverse
transcriptase-polymerase chain reaction, and Western
blotting, direct effects of the glucocorticoid dexamethasone
at concentrations designed to mimic in vivo therapeutic
corticosteroid levels. Dexamethasone upregulated expression
of nephrin and tubulin-a, and downregulated vascular
endothelial growth factor. Effects on cell cycle were complex
with downregulation of cyclin kinase inhibitor p21 and
augmentation of podocyte survival, without any effect on
apoptosis. We report cytokine production by human
podocytes, especially interleukin (IL)-6 and -8; IL-6 expression
was suppressed by dexamethasone. These potent direct
effects on podocytes illustrate a novel mode of action of
glucocorticoids and suggest potential new therapeutic
strategies for glomerular disease.
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Glucocorticoids exert potent effects on leukocytes and cells of
the immune system, forming the mainstay of treatment for
many human inflammatory diseases. Their effectiveness in
diseases where there is no evident inflammation is more
difficult to understand: one conspicuous example is minimal
change nephropathy, a major cause of nephrotic syndrome
especially in children. Nephrotic syndrome is characterized
by massive leakage of protein into the urine: the disease and
its treatment cause major morbidity and mortality.1 For
decades, it has been assumed that immunological distur-
bances underlie this condition, with effectiveness of gluco-
corticoids being cited in the seminal paper by Shalhoub2 as
one of the best lines of evidence for this assumption. Recent
evidence from knockout mice and rare single human gene
disorders emphasizes the importance of podocytes (visceral
glomerular epithelial cells) in nephrotic syndrome: defects of
the podocyte-specific gene nephrin3,4 cause congenital
nephrotic syndrome; mutations in another podocyte-specific
gene podocin5 also cause severe early-onset nephrotic
syndrome. Deletion in mice of CD2-associated protein,
which associates with nephrin,6 causes congenital nephrotic
syndrome.7 The limited ability of podocytes to replicate and/
or repair may underlie the tendency for glomerular diseases
to progress to scarring (glomerulosclerosis).8,9 We tested the
hypothesis that glucocorticoids exert direct effects on
podocytes. Previously, the only available human podocytes
were transformed cell lines or undifferentiated primary
culture cells: these cells are not considered representative of
mature podocytes. We developed conditionally immortalized
human podocytes using a temperature-sensitive transgene:
when cells are moved to the non-permissive temperature of
371C, the transgene is silenced and cells develop a mature
podocyte phenotype.10 We now report potent direct effects
of the glucocorticoid dexamethasone on these cells, at
concentrations designed to mimic in vivo therapeutic
corticosteroid levels. Our results illustrate a novel mode of
action of glucocorticoids, suggesting that efficacy of these
drugs in nephrotic syndrome may not be explained by
conventional anti-inflammatory or immunosuppressive
actions. The data add to evidence that the podocyte is the
key cell in human glomerular disease and suggest novel
therapeutic strategies.
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RESULTS
Expression of glucocorticoid receptors by podocytes
First, we confirmed that expression of glucocorticoid
receptors by podocytes, as previously reported in human
kidney sections,11 was replicated by our podocyte cell line in
vitro. Glucocorticoid receptors were present in both nuclear
and cytoplasmic extracts (Figure 1). There was a suggestion
that overall level of expression and nuclear localization of
glucocorticoid receptors, quantitated by Western blotting in
whole-cell lysates and in nuclear extracts, was upregulated
by dexamethasone in a dose-dependent manner, although
this only achieved statistical significance in cell lysates
with 105 M dexamethasone and in nuclear extracts with
107 M dexamethasone (Figure 1).
Effects of dexamethasone on podocyte maturation at 371C
and expression of nephrin and tubulin a
When these conditionally transformed cells are cultured at
the permissive temperature of 331C, the transgene is active
and cells proliferate into a cobblestone epithelial monolayer
similar to that seen with primary culture cells.10 When moved
to non-permissive temperature of 371C, the transgene is
silenced, cells mature and form complex processes, assuming
the phenotype of mature podocytes.10 Maturation was
enhanced and accelerated by dexamethasone: processes
started to form at days 12 and 13 without dexamethasone,
at days 10 and 11 with 107 M dexamethasone, and at days 7
and 8 with 105 M dexamethasone.
Nephrin expression was upregulated after 14 days
incubation with dexamethasone (Figure 2). Immunofluore-
scent staining is not regarded as a quantitative technique, but
there is a striking difference in the amount of fluorescence
seen in images taken on identical exposure settings with anti-
nephrin rabbit polyclonal antibody K2966 according to the
presence or absence of dexamethasone in the culture medium
for 14 days (Figure 2a, no dexamethasone, Figure 2b, cells
incubated with 105 M, Figure 2c negative control immuno-
fluorescence with rabbit immunoglobulin (Ig) for compar-
ison). Quantitation by Western blot with rabbit polyclonal
anti-nephrin antibody K2737 confirmed dose-dependent
upregulation of nephrin protein by dexamethasone (Figure
2d, representative of five replicate experiments). Nephrin is a
large-molecular-weight membrane-bound protein and is
known to be difficult to blot, accounting for the indistinct
bands. We therefore show detailed densitometric quantifica-
tion of three replicate Western blots, which showed nephrin/
actin ratios of 1.0:1.33:1.618 with 0, 107, and 105 M
dexamethasone, respectively (Po0.05, Figure 2e). Reverse
transcriptase-polymerase chain reaction (RT-PCR) suggested
that this effect was at least partly at the RNA level (Figure 2f,
representative of five replicate experiments). Expression
of other key podocyte proteins, including podocin,5
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Figure 1 | Effects of dexamethasone on expression of
glucocorticoid receptors in human podocytes. (a) Representative
Western blot on whole-cell lysates and nuclear extracts.
(b) Densitometry of five replicate Western blots for cell lysates,
and three replicate Western blots for nuclear extracts (*Po0.05,
**Po0.01). (c) RT-PCR on podocyte RNA using primers for
glucocorticoid receptor (GR) and control ‘housekeeping’ gene
(GAPDH) (representative of three replicate experiments).
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Figure 2 | Effects of dexamethasone on the expression of
nephrin in human podocytes. (a–c) Effect of incubation with
dexamethasone on expression of nephrin in human podocytes by
immunofluorescence with rabbit polyclonal antibody K2966 (all
pictures taken at identical exposure settings, green staining indicates
nephrin protein present). (a) Incubation in standard culture medium,
without dexamethasone for 14 days with medium changed on
alternate days. (b) Incubation with standard medium plus 105 M
dexamethasone for 14 days with medium changed on alternate days.
(c) Negative control immunofluorescence on podocytes incubated
with standard medium plus 105 M dexamethasone for 14 days with
medium changed on alternate days, using rabbit Ig instead of
primary antibody. (d) Western blot on podocyte whole-cell lysate
using rabbit polyclonal anti-nephrin antibody K2737 (representative
of five replicate experiments). (e) Densitometric quantification of
three replicate Western blots, expressed as nephrin/actin ratio
(mean7s.e.m.). Mean ratio for 0:107:105 M¼1:1.33:1.618 (*Po0.05).
(f) RT-PCR on podocyte RNA using primers for nephrin and
‘housekeeping’ gene GAPDH (representative of five replicate
experiments).
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CD2-associated protein,7 and synaptopodin10 was unaffected
by dexamethasone (data not shown).
Enhanced podocyte maturation and formation of major
processes with dexamethasone was accompanied by increased
expression of microtubule protein tubulin a, quantitated by
densitometry of Western blots (Figure 3a and b). RT-PCR
(Figure 3c, representative of three replicate experiments)
suggested that upregulation was at least partly at the RNA
level.
Effects of dexamethasone on apoptosis and podocyte
number
In many cell types, dexamethasone induces apoptosis.12,13
However, dexamethasone had no effect on apoptosis in
podocytes: percentage apoptotic cells, respectively, with 0,
107, and 105 M dexamethasone were 3.7, 3.0, and 3.7 at
331C, and 4.7, 4.3, and 6.0 at 371C (P40.05). Despite this
lack of effect on apoptosis, dexamethasone significantly
enhanced podocyte number. Under permissive (331C)
conditions, cell index (ratio of number of cells compared to
baseline) was 2.100 at day 7. This was increased to 3.537 by
107 M dexamethasone (Po0.01) and to 2.639 by 105 M
dexamethasone (Po0.05). We speculated that this enhance-
ment of podocyte number was owing to increased survival of
individual cells, and tested this using long-term podocyte
culture. When cultured for 60 days at 371C without
dexamethasone, 34.6% of podocytes survived. At a wide
range of dexamethasone concentrations, podocyte survival
was enhanced, percentage survival at day 60 being 75.4, 80.6,
67.5, 69.2, and 87.6 respectively, at day 60 with 108, 107,
106, 105, and 104 M dexamethasone.
Effects of dexamethasone on p21 in differentiated podocytes
Expression of cyclin kinase inhibitor p21 was assessed by
immunocytochemistry and Western blotting in podocytes.
Without dexamethasone, all cells were p21 positive, although
intensity of p21 staining was variable. Dexamethasone mark-
edly reduced intensity of staining and percentage of cells
staining positive. The effects were quantified by Western blot
on whole-cell lysates (Figure 4), confirming downregulation
of p21 protein.
Effects of dexamethasone on transcription factor expression
We studied transcription factor GATA-3 because of its
possible role in the regulation of nephrin expression: the
nephrin promoter contains multiple putative GATA-3 bind-
ing domains.14 By immunocytochemistry, all podocyte nuclei
expressed GATA-3. Dexamethasone caused marked down-
regulation of GATA-3 protein quantified by Western blotting
and GATA-3 RNA on RT-PCR (Figure 5). Other transcription
factors analyzed were nuclear factor (NF)-kB and NF-1: both
were abundantly expressed by podocytes but unaffected by
dexamethasone (data not shown).
Effects of dexamethasone on VEGF expression
Expression of vascular endothelial growth factor (VEGF) was
analyzed by immunocytochemistry, Western blotting, and
RT-PCR (Figure 6). VEGF is differentially spliced in
podocytes;15,16 available antibodies do not discriminate
between isoforms so that isoform expression pattern can
only be assessed at mRNA level. In differentiated podocytes,
VEGF was expressed in a linear distribution in cytoplasm and
in cell processes. Dexamethasone downregulated VEGF
expression; with 105 M dexamethasone, VEGF expression
was virtually absent by immunofluorescence. Quantitative
effects were confirmed by Western blotting (Figure 6a and b,
representative of three replicate experiments, Po0.01).
RT-PCR showed that podocytes expressed mRNA for at
least three VEGF isoforms (VEGF121, 165, 189).
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Figure 3 | Effects of dexamethasone on the expression of tubulin
a in human podocytes. (a) Western blot on whole-cell lysate
(representative of three replicate experiments). (b) Densitometry of
three replicate Western blots (*Po0.05, **Po0.01). (c) RT-PCR on
podocyte RNA using primers for tubulin a and ‘housekeeping’ gene
GAPDH (representative of three replicate experiments).
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Figure 4 | Effects of dexamethasone on the expression of cyclin
kinase inhibitor p21 in human podocytes. (a) Western blot on
whole-cell lysates (representative of three replicate experiments).
(b) Densitometry of three replicate Western blots (*Po0.05,
**Po0.01).
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Dexamethasone downregulated all three isoforms, but
particularly VEGF165 and 189 (Figure 6c, representative
of three replicate experiments).
Cytokine expression by podocytes; effects of dexamethasone
Supernatants of cultured mature human podocytes contained
pg/ml quantities of interleukins (IL)-6 and -8 but no
detectable IL-1b, IL-2, IL-4, IL-10, IL-12, tumor necrosis
factor-a, or interferon-g. The effect of dexamethasone
treatment of mature cells for 48 h was tested because cytokine
expression was expected to be rapid and maximal within this
time period. Furthermore, the short half-life of secreted
cytokines made it important to test at early time periods.
Dexamethasone suppressed IL-6 production (fluorescence
intensity in cytokine bead array, mean7s.d., 15027619
without Dex to 8787342 after 48 h with 105 M Dex, n¼ 9,
two-tailed P¼ 0.0039, Wilcoxon non-parametric paired
analysis) but had no effect on IL8.
DISCUSSION
Nephrotic syndrome, especially in childhood, often responds
to treatment with corticosteroids: this is unlikely to be owing
to conventional anti-inflammatory effects of these drugs
since steroid-sensitive nephrotic syndrome is typically
associated with complete absence of glomerular inflam-
mation. Other possible mechanisms of the beneficial effect of
corticosteroids could include direct protection of podocytes
from injury and/or promotion of podocyte repair. We were
interested to test the hypothesis that the typical glucocorti-
coid dexamethasone has direct effects on human podocytes.
Such studies have previously been hampered by lack of
suitable cell lines: we have developed conditionally trans-
formed human podocytes, which at 371C differentiate into a
phenotype closely resembling mature podocytes.10 We found
that dexamethasone has potent direct effects on human
podocytes in vitro.
The podocyte is a highly specialized and complicated cell
that plays a critical role in the kidney in health and
disease.17–19 Recent advances have highlighted the impor-
tance of podocytes in nephrotic syndrome, where the
glomerular filtration barrier is disrupted and there is massive
leakage of protein into urine.19,20 The podocyte-specific gene
nephrin seems particularly important: mutations of this gene
in man cause congenital nephrotic syndrome of Finnish type3
and nephrin-deficient mice also develop congenital nephrotic
syndrome.4 Regarding acquired forms of nephrotic syndrome
in man, an early report suggested that nephrin expression was
reduced.21 This remains controversial, soon being confirmed
by one report22 but refuted by another.23 However, there is
general agreement that the podocyte is an important target of
injury in many forms of acquired nephrotic syndrome.20,24,25
As mentioned earlier, defective repair mechanisms in
podocytes may underlie the tendency for many glomerular
diseases to lead to progressive scarring culminating in kidney
failure.8,9 In particular, it is believed that the limited capacity
of podocytes to replicate hampers their ability to repair
themselves and/or replace injured podocytes with new
progeny.26 In health, podocytes are restrained from entry
into cell cycle by a complex array of inhibitory molecules.26
In diseases characterized by podocyte injury, including
glomerulonephritis and diabetic nephropathy, normal reg-
ulation of these inhibitors is disturbed and in particular the
cyclin kinase inhibitor p21 is upregulated.26–28 Our data
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Figure 5 | Effects of dexamethasone on the expression of
transcription factor GATA-3 in human podocytes. (a) Western blot
on nuclear extract (representative of three replicate experiments,
Po0.01) (b) Densitometry of three replicate Western blots (*Po0.05,
**Po0.01). (c) RT-PCR on podocyte RNA for GATA 3 and ‘house-
keeping’ gene GAPDH (representative of three replicate experiments).
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Figure 6 | Effects of dexamethasone on the expression of VEGF
in human podocytes. (a) Western blot on whole-cell lysate
(representative of three replicate experiments). (b) Densitometry of
three replicate Western blots (*Po0.05, **Po0.01). (c) RT-PCR on
podocyte RNA:VEGF primers amplify multiple isoforms of VEGF
(representative of three replicate experiments).
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showing that dexamethasone leads to marked downregu-
lation of p21 expression may therefore be particularly
significant: podocyte proliferation and repair may require
the ‘molecular brake’ to be taken off and release of cell cycle
inhibition by downregulation of p21 could allow this to
occur.
Concentrations of dexamethasone were based on calcula-
tions of ‘therapeutic’ concentrations in vivo. Loew et al.29
found peak plasma dexamethasone concentrations of
0.8870.15 107 M in normal humans after intramuscular
injection of 3 mg dexamethasone. After intravenous injection
of 1.0 g methylprednisolone, dexamethasone-equivalent
peak concentration (adjusted for glucocorticoid potency)
was 2.95–8.49 106 M.30 Patients with nephrotic syndrome
receiving high-dose oral or intravenous prednisolone had
peak concentrations of total and unbound prednisolone
in plasma of about 450 and 173 mg/ml, respectively.31
Equivalent dexamethasone concentrations, incorporating
a correction factor for glucocorticoid potency, are 1.72
107 and 0.66 107 M, respectively. To be consistent with
clinical doses of glucocorticoid used in the treatment of
glomerular diseases, we therefore chose for our quantitative
analyses, the concentrations of dexamethasone of 1 107
and 1 105 M.
Glucocorticoids exert cellular effects by binding to
glucocorticoid receptors in cytoplasm, forming dimers and
being translocated into the nucleus where they bind to
glucocorticoid response elements in DNA, or interact with
other transcription factors, thus regulating transcription of
many genes.32 Glucocorticoid receptors are known to be
expressed by podocytes in human kidney,11 and we have
found that human podocytes in vitro also express gluco-
corticoid receptors in the expected nuclear and cytoplasmic
distribution; dexamethasone caused modest upregu-
lation and increased nuclear localization of glucocorticoid
receptors. In other cell-types, glucocorticoids have been
shown to have varied effects on glucocorticoid receptor
expression.33
We found that dexamethasone enhanced and accelerated
podocyte maturation, with a particularly striking effect on
expression of nephrin. Nephrin is a key component of the slit
diaphragm, the main site of control of glomerular permea-
bility. Our data suggest that dexamethasone-induced upre-
gulation of nephrin occurred at least partly at the RNA level.
This interpretation must be cautious however: simple RT-
PCR is not reliable for quantitation and future studies should
use Northern blotting and/or fully quantitative PCR. Our
finding that GATA-3 was downregulated does not support
the suggestion that GATA-3 is important in nephrin gene
transcription. Podocin, CD2-associated protein, and synap-
topodin were not affected by dexamethasone.
Dexamethasone enhanced podocyte survival without any
effect on apoptosis. In other cell types, glucocorticoids have
variable effects on proliferation, differentiation, and apopto-
sis; clearly, there are cell-type-specific effects.12,13 In human
and experimental studies, it has been suggested that the
inability of the mature podocyte to undergo mitosis is
responsible for the development of glomerulosclerosis and
progression of glomerular disease.8,9 However, in some forms
of glomerular disease including HIV-associated nephropathy,
unregulated podocyte proliferation does occur in response to
injury, and is considered deleterious.34 Clearly, novel forms of
therapy aimed at allowing podocyte repair would need to be
carefully targeted to prevent excessive podocyte proliferation.
Our data suggest that p21 may be a particularly important
target.
VEGF is a mitogen for vascular endothelial cells, plays an
important role in vasculogenesis and angiogenesis, and
induces vascular leakage and vasodilation.15 In normal
glomeruli, VEGF is expressed exclusively by podocytes35
and is differentially spliced into isoforms (VEGF121, 148,
165, 189), which are thought to differ in tissue-binding
characteristics and functions.15,16 Upregulation of VEGF in
renal tissue from patients with minimal change nephropathy
compared to controls and other glomerular disease has been
reported,36,37 so an effect of glucocorticoids to downregulate
VEGF expression may be beneficial.
Cytokine production by podocytes may provide the
previously elusive link38 between the podocyte and the
immune system. Local production of IL-6 by podocytes may
contribute to the pathogenesis of nephrotic syndrome, so
that its suppression by corticosteroids is intriguing.
Putting our observations together, we propose the
following mechanistic hypothesis. In nephrotic syndrome,
podocytes lose the complex processes that characterize their
differentiated state. Expression of nephrin is disrupted.
Corticosteroids act directly on podocytes to promote repair,
with enhanced process formation and upregulation of
nephrin. We speculate that the downregulation of p21, which
normally acts as a molecular ‘brake’ on podocytes’ ability to
enter the cell cycle,26,27 is important in allowing this to occur.
Thus, the podocyte’s limited ability to repair itself, thought to
lie behind the importance of this cell type in progressive
glomerular injury,9 can be overcome by exogenous cortico-
steroid. Novel approaches to therapy for nephrotic syndrome
should concentrate on measures aimed at enhancing
podocyte repair and nephrin expression. Our cell line will
provide a valuable tool for assessment of these approaches.
Consistent with these ideas are our recent observations39 that
incubation with plasma from patients with active nephrotic
syndrome, but not from the same patients in remission,
induces marked phenotypic changes in human podocytes
with loss of process formation and downregulation of
nephrin expression, that is, opposite changes to those seen
after treatment of the cells with dexamethasone. In mouse
podocytes, a recent proteomic analysis reported effects of
dexamethasone on numerous genes.40 A possible functional
relevance of these observations is illustrated by a previous
report that dexamethasone protected mouse podocytes in
vitro from the permeability-increasing effects of adria-
mycin.41 Thus, evidence is accumulating to support the
importance of corticosteroids’ effects on podocytes as an
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explanation for their beneficial therapeutic effects in
glomerular disease.
In summary, the glucocorticoid dexamethasone has direct
effects on human podocytes through regulating glucocorti-
coid receptors, cell maturation and survival, cytoskeleton,
and expression of key proteins nephrin, VEGF, and IL-6. The
direction of these changes would be beneficial in reversing
pathological changes observed in steroid-sensitive nephrotic
syndrome. Together with recent observations that emphasize
the primary role of the podocyte in many forms of
glomerular disease, this leads us to suggest that the effects
of glucocorticoids in nephrotic syndrome may have little to
do with conventional anti-inflammatory or immunosuppres-
sive actions of these drugs, instead reflecting modulation of
podocyte biology and promotion of podocyte repair
mechanisms.
MATERIALS AND METHODS
Podocyte culture
Conditionally immortalized human podocytes were derived and
cultured as reported:10 from a discarded nephrectomy specimen
from a 3-year-old child whose parents gave full informed consent.
Passage numbers of cells were between 5 and 18, batches of cells of
same passage number being used for each set of experiments.
Replicate experiments were performed (number of experiments is
stated in each case below) and representative results are shown.
Medium, with or without added dexamethasone as appropriate, was
changed on alternate days throughout.
Treatment with dexamethasone
Dexamethasone-water soluble (Sigma-Aldrich Co., Poole, UK) was
dissolved in culture medium at concentrations ranging from 108 to
102 M; fresh dexamethasone-containing medium or control med-
ium was supplied on alternate days. As control in each study, cells
were cultivated contemporaneously for the same number of days in
culture medium without dexamethasone. Unless otherwise stated,
results shown are after 14 days treatment with dexamethasone or
control. Detailed quantitative assessments were mainly based on the
comparison between 0, 107, and 105 M dexamethasone, as these
latter two concentrations equate to ‘therapeutic’ concentrations
achieved in vivo (see, Discussion).
Antibodies and control Igs
Primary antibodies were as follows: mouse monoclonal and rabbit
polyclonal anti-nephrin (kind gifts of Dr Karl Tryggvason); rabbit
polyclonal anti-podocin (kind gift of Dr Corinne Antignac); and
mouse monoclonals anti-tubulin a (Zymed Laboratories, South San
Francisco, CA, USA), anti-p21, anti-GATA-3, rabbit polyclonals anti-
glucocorticoid receptor, anti-VEGF (all Santa Cruz Biotechnology,
Santa Cruz, CA, USA). Secondary antibodies were: fluorescein
(fluorescein isothiocyanate)-conjugated affinity-purified goat anti-
mouse or anti-rabbit IgG (Jackson ImmunoResearch Laboratories,
West Grove, PA, USA). Controls were as follows: mouse-IgG1
(Sigma-Aldrich Co.), mouse-IgG, rabbit-IgG, and goat-IgG (Santa
Cruz).
Cell number – MTS assay
Cell number was measured using MTS (Promega, Southampton,
UK), which is bioreduced into a soluble formazan that can be
quantitated by spectrophotometry and is directly proportional to
the number of living cells. Standard curves were obtained using
known numbers of cells.
Apoptosis – TUNEL assay
Apoptosis was measured by terminal deoxynucleotide transferase
(TdT)-mediated dUTP-fluorescein isothiocyanate nick-end labeling
(TUNEL) assay (Promega kit).
Immunofluorescence
Cells were grown on collagen type I-coated glass coverslips, fixed
with paraformaldehyde, and then permeabilized with Triton X-100.
Nonspecific binding was blocked with 3% bovine serum albumin
plus species-control IgG. Primary antibodies were applied at one in
100 dilution in blocking buffer for 60 min at room temperature.
After washing, cells were incubated with secondary antibodies diluted
one in 100 in blocking buffer. Results were visualized by immuno-
fluorescence microscopy, photographed with a digital camera.
RT-PCR
Total RNA was extracted by phenol–chloroform guanidine thio-
cyanate (Promega). Total RNA (0.5–1.0mg) was reverse transcribed
using Promega’s Reverse Transcription System. Table 1 shows PCR
primers, predicted product sizes, and amplification conditions.
cDNA (0.5–3 ml) was added to final volume 25ml, containing 10 pM
Table 1 | Primers and PCR conditions
Name Forward primer Reverse primer
Product
size (bp)
Annealing
temperature (1C) Cycles
Nephrin 50-GAC CGA GTC AGG 50-CCT GTG AAA CCT 170 58 40
AAC GAA TA-30 CGG GAA TA-30
Tubulin a 50-TCG CAA GCT GGC 50-TTG GGA ACC ACG 612 64 30
TGA CCA GT-30 TCA CCA CG-30
VEGF 50-GTG AAT GCA GAC-30 50-AAA CCC TGA GGG-30 96, 228, 300, 351 58 40
Isoforms 50-CAA AGA AAG-30 50-AGG CTC-30
GATA-3 50-AGG TAC CCT CCG 50-CTC AAG TAC CAG 350 55 35
ACC CAC CA-30 GTG CCC CT-30
GAPDH 50-GTA GAG GCA GGG-30 50-GCT GTA GGA AGC-30 287 56 30
50-ATG ATG TT-30 50-TCATCTCT-30
GAPDH, glyceraldehyde-3-phosphate; PCR, polymerase chain reaction; VEGF, vascular endothelial growth factor.
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of each primer, 1–2.5 U of Taq DNA polymerase, 1.5–2.5 mM MgCl2,
and 100 mM of dNTPs. Products were electrophoresed in 2% agarose
and visualized by ethidium bromide staining. In semiquantitative
experiments, the housekeeping gene glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was coamplified for comparison.
Western blot
Total cell lysates were prepared from podocytes using radio-
immunoprecipitation assay buffer (Sigma-Aldrich). Nuclear extracts
were prepared using NuclearTM Extraction Kit (Sigma-Aldrich).
Proteins were separated by 8% reducing sodium dodecyl sulfate–-
polyacrylamide gel electrophoresis and transferred to nitrocellulose
membranes (Sigma-Aldrich). After blocking with bovine serum
albumin plus dry milk (Sigma-Aldrich) and control IgG, mem-
branes were incubated sequentially with primary antibodies diluted
one in 500 in blocking buffer, horseradish peroxidase-conjugated
secondary antibodies diluted one in 10 000 (for monoclonal
primary) or one in 20 000 (for polyclonal primary), followed by
Chemiluminescence Luminol Reagent (Santa Cruz). X-ray film was
exposed to membrane, developed, and scanned. In all experiments,
protein loading was standardized by preliminary experiments in
which actin expression was quantitated. Blots were then probed for
protein of interest band intensity assessed by densitometry.
Densitometry
Gels were scanned by densitometry and analyzed by Labworks 4.0
(UVP Inc., Upland, CA, USA).
Cytokine expression
Culture supernatants were analyzed using cytokine bead array
(Becton Dickinson, Oxford, UK), which allows simultaneous
measurement of multiple cytokines: IL-1b, -2, -4, -6, -8, -10, and
-12, tumor necrosis factor-a, and interferon-g. Supernatants were
incubated with beads for 1 h at room temperature then analyzed by
flow cytometry. Manufacturer’s standards allow quantitation of each
cytokine, the fluorescence intensity with each bead size being
proportional to the concentration of individual cytokines.
Statistical analysis
Statistical analysis was performed using SPSS10 software. Pooled
results from replicate quantitative experiments were compared by
analysis of variance. Two-tailed P-values of less than 0.05 were taken
as indicating statistical significance.
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